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A B S T R A C T
We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in
the first injection for treatment of refractory diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory
DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL
and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Second-
ary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse
events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT
change compared to the baseline was –95.7 mm (95% CI, –172.2 to –19.26) in the IVB group and –92.1 mm (95% CI, –154.4
to –29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=
0.022). Improvement of BCVA was initiated at weeks 6 and 12 in the IVB/IVT and IVB groups respectively. In terms of
BCVA change compared to the baseline at 24 weeks, the differences between the IVB and the IVB/IVT groups (p=0.006)
were significant. Anterior Chamber reaction was noticed in six (20%) and six (20%) eyes respectively in the IVB and
IVB/IVT groups the day after injection, and it resolved with no sequel. Elevation of IOP occurred in two eyes (6%) in the
IVB/ IVT group. Intravitreal injections of Bevacizumab had a beneficial effect on refractory DME in terms of CMT reduc-
tion and BCVA improvement. Addition of triamcinolone in the injection seemed to induce earlier visual improvement;
however, it did not show any significant additive effect later during follow-up.
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Introduction
Macular oedema is a predominant cause of visual im-
pairment in diabetic patients. The Early Treatment Dia-
betic Retinopathy Study (ETDRS) showed that focal la-
ser photocoagulation is effective in reducing the risk of
visual loss in eyes with clinically significant macular
oedema1. Laser treatment, however, has limited results
in eyes with diffuse diabetic macular oedema (DME)1,2.
The poor response of diffuse DME to laser photocoagu-
lation has prompted interest in other treatment modali-
ties. Multiple studies have shown that a single intra-
vitreal injection of triamcinolone acetonide (IVT) may
have a rapid effect in eyes with diffuse diabetic macular
oedema resistant to laser therapy. This therapeutic ef-
fect, however, decreases with the disappearance of intra-
vitreal triamcinolone3–5.
Recent research has revealed the role of the vascular
endothelial growth factor (VEGF) in inducing vascular
hyper permeability5,6. It has been shown that vitreous
samples from eyes with DME show elevated VEGF le-
vels5.
According to these findings, anti-VEGF medications
may have a critical role in prevention and/or treatment
of DME. A recent clinical trial revealed the beneficial ef-
fect of pegaptanib on diabetic macular oedema7. Bevaci-
zumab, a humanized full-length monoclonal antibody
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that inhibits all isoforms of VEGF, has also been used for
treatment of refractory DME.
We conducted randomized clinical trial to evaluate
the morphological effect of three repeated injections of
intravitreal Bevacizumab (IVB), either alone or in combi-
nation with triamcinolone acetonide in the first injec-
tion, for the treatment of refractory DME8–11. The 24-
-week results of this clinical trial are presented in this re-
port.
Materials and Methods
The study protocol was explained to all patients, and
informed consent was obtained. Patients were referred
to the Ophthalmic Research Center by co investigators in
the participating centers.
Participants
Eyes with clinically significant macular oedema unre-
sponsive to previous macular laser photocoagulation,
with the last session being more than 3 months prior,
were included.
Exclusion criteria consisted of visual acuity =20/40,
history of cataract surgery within the past 6 months,
prior intraocular injection or vitrectomy, glaucoma or oc-
ular hypertension, proliferative diabetic retinopathy
(PDR) with high-risk characteristics, vitreous hemor-
rhage, significant media opacity, and presence of traction
on the macula. Monocular patients were excluded. Preg-
nancy and serum creatinine level =3 mg/100 were also
among the exclusion criteria.
Interventions
All participants were questioned about the duration
and management of their diabetes mellitus, history of
systemic hypertension, smoking, and panretinal photo-
coagulation (PRP). Dates of previous macular laser pho-
tocoagulation were recorded. Best corrected visual acuity
(BCVA), presence and extent of neovascularization of iris
(NVI), degree of lens opacity in phakic eyes, intraocular
pressure (IOP), and severity of diabetic retinopathy were
also recorded. Best corrected visual acuity (BCVA) mea-
sured by Snellen chart was recorded by the logarithm of
the minimum angle of resolution (logMAR). Lens opacity
was graded from 0 to 4+ by observers using the Lens
Opacities Classification System III (LOCS III) for each of
three different categories including nuclear sclerosis,
posterior sub capsular opacities, and cortical cataract4.
The anterior chamber inflammatory reaction was evalu-
ated using slit lamp bio microscopy. The extent of NVI
and severity of diabetic retinopathy were expressed in
clock hours and ETDRS scaling respectively. Baseline an-
cillary diagnostic tests including fundus photography,
fluorescein angiography (FA), and optical coherence to-
mography (OCT) were performed before intervention.
Fundus photography was performed with a Topcon Fun-
dus Camera (TRC-NW7SF) using a 50° field centred on
the fovea. Optical coherence tomography was performed
by a trained optometrist using commercially available
equipment spectral OCT (OTI, Canada). All OCT scans
were acquired using macular thickness map protocol by a
standard mode and proper scanning centralization. The
OCT examination was comprised of six radial 6 mm-long
scans of each eye centered on the patient’s fixation point.
This mapping averaged the six scans to give the central
macular thickness (CMT) in a central area 1 mm in di-
ameter. The same protocol was repeated at each fol-
low-up visit. To reduce the effect of diurnal variation on
macular thickness measurement, all scans were per-
formed between 9 and 11 a.m. Eligible eyes were ran-
domly assigned to one of the two study arms, which uti-
lised intravitreal Bevacizumab (IVB group), combined
intravitreal Bevacizumab and triamcinolone (IVB/IVT
group).
Surgical technique
Injections were done under sterile conditions with
topical anesthesia and insertion of a lid speculum. For
the IVB group, 1.25 mg (0.05 cc) Bevacizumab (Avastin,
Roche Pharma AG), was injected intravitreally with a
30-gauge needle through the superotemporal quadrant.
For the IVB/IVT group, there is a mixture in one syringe
e.g. 1.25 mg Bevacizumab and 2 mg (0.05 cc) triamcino-
lone acetonide (Triaminject, WINTHROP, Germany) was
injected intravitreally through the superotemporal quad-
rant.
Second and third injections of the IVB/IVT group con-
sisted of only Bevacizumab (1.25 mg) according OCT
finding. All eyes underwent an ophthalmic examination,
checking 1 and 7 days after each injection for anterior
chamber (AC) reaction and IOP rise. Complete ophthal-
mologic examination and OCT were performed before
the second and third injections, and at 18 and 24 weeks
after the first intervention. Fluorescein angiography was
repeated at 24 weeks after the initial intervention.
Outcome measures
The primary outcome measure was change in CMT
compared to baseline. Central macular thickness was de-
fined by the average thickness of a central macular re-
gion 1,000 mm in diameter centered on the patient’s
foveola. Secondary outcome measures included change in
best-corrected logMAR visual acuity, IOP rise, cataract
progression, intraocular inflammation, and any other se-
rious adverse effect.
Randomization
Randomization was performed using a random block
permutation method according to a computer-generated
randomization list. The block lengths varied random-
ly1,12. A random allocation sequence was performed by a
biostatistician. Details of the series were unknown to the
investigators. Masking Subjects were masked to the
treatment modality.
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Sample size
To have a power of 90%, a level of significance equal
to 0.05 and an assumed standard deviation of 50 mm, a
minimum sample size of 30 eyes for each arm was calcu-
lated to detect a 30% difference in CMT changes between
the two treatment groups.
Statistical analysis
Patient data was recorded in data collection sheets.
Statistical analysis was performed with SPSS software
(Statistical Package for Social Sciences version 13.0,
SPSS Inc. Chicago, IL, USA). Qualitative variables were
expressed. Using percentages and quantitative data were
explained with mean, standard deviation, and/or confi-
dence interval. T-test, chi-square test, and analysis of
variance (ANOVA) were used for inferential statistics. A
normal distribution of the quantitative data was checked
using the Kolmogorov-Smirnov test. The level of signifi-
cance was 0.05 (p=0.05). To rule out the possible effect of
the intravitreally injected drug(s) on the other eye, all
statistical analyses were repeated after excluding pa-
tients with both eyes in the study.
Results
Sixty eyes of 60 patients were assessed for eligibility
criteria. The mean (±SD) age of patients was 59.7±8.3
years (range, 39–74 years). Twenty nine patients (48%)
were male and 31 (52%) were female. There was a history
of cataract surgery in 3 eyes (10%). Nonproliferative dia-
betic retinopathy (NPDR) was present in 24 eyes (80%),
early proliferative diabetic retinopathy in two eyes (6%),
and regressed proliferative diabetic retinopathy in 3 eyes
(10%). Iris neovascularization was not detected in any
eye at presentation. History of smoking and systemic hy-
pertension was positive in 3 (10%) and 10 (30%) patients
respectively. The eligible eyes were randomized into two
groups: 30 eyes in the IVB group, 30 eyes in the IVB/IVT
group. Mean HbA1c level was 9.95 mg/dL in the IVB
group, 9.35 g/dL in the IVB/IVT group. In terms of diabe-
tes control, 20.3% and 27.6% of patients were on insulin
in the IVB and IVB/IVT groups respectively. There was
no significant difference among the groups regarding the
above-mentioned parameters. The groups were matched
for age, sex, baseline visual acuity, systemic hyperten-
sion, history of smoking, stage of diabetic retinopathy,
number of previous laser sessions at the macula, and his-
tory of PRP (p>0.05). However, the groups were not
matched for CMT before treatment. Statistical analyses
were performed after adjustment of the parameters ac-
cording to their baseline values. Mean of changes in CMT
and BCVA in each follow-up visit compared to the base-
line are presented in Table 1. The difference between ini-
tial and the treatment groups in terms of CMT changes
appeared 6 weeks after the first injection, and persisted
until 24 weeks. Considering BCVA changes, significant
improvement was initially observed at weeks 6 and 12 in
the IVB/IVT and IVB groups respectively. Changes in
BCVA remained statistically significant for both treat-
ment groups up to 24 weeks (Table 2). At week 24, CMT
change compared to the baseline was –95.7 mm (95% con-
fidence interval, –172.2 to –19.3) in the IVB group, –92.1
mm (95% confidence interval, –154.4 to –29.7) in the
IVB/IVT group. ANOVA and subsequent pairwise com-
parison tests (using the Bonferroni test) showed no sta-
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TABLE 2
MEAN DIFFERENCES OF CMT AND BCVA CHANGES IN A PAIRWISE COMPARISON AMONG THE GROUPS AT EACH FOLLOW UP VISIT
Intervation (I) Intervation (J)
BCVA (logMAR) CMT(µ)
Mean diff.(I–J) p value Mean diff. (I–J) p value
Week 6 IVB IVB/IVT 0.08±0.04 0.169 4±27 0.999
Week 12 IVB IVB/IVT 0.06±0.06 0.994 31±27 0.786
Week 18 IVB IVB/IVT 0.002±0.06 0.999 62±35 0.253
Week 24 IVB IVB/IVT 0.02±0.06 0.999 –3±42 0.999
BCVA – Best corrected visual acuity, CMT – Central macular thickness, IVB – Intravitreal bevacizumab,
IVT – Intravitreal triamcinolone
TABLE 1
MEAN (±SD) OF CHANGES IN CENTRAL MACULAR THICKNESS AND BEST CORRECTED VISUAL ACUITY IN RELATION TO
THE BASELINE
Base line 6 weeks 12 weeks 18 weeks 24 weeks
CMT change(µ)
IVB –87.7±114 –70±134 –50±104 –94±170
IVB/IVT –92±140 –101±110 –112±120 –93±124
BCVA change(logMAR)
IVB –0.75±0.1 –0.1±0.2 –0.2±0.2 –0.2±0.2
IVB/IVT –0.1±0.2 –0.2±0.2 –0.2±0.2 –0.2±0.2
BCVA – Best corrected visual acuity, CMT – Central macular thickness, IVB – Intravitreal bevacizumab,
IVT – Intravitreal triamcinolone
tistically significant difference between the IVB and the
IVB/IVT (p=0.99) groups (Table 2). BCVA change at
week 24 compared to the baseline BCVA was –0.18
logMAR (95% confidence interval, –0.29 to –0.08) in the
IVB group, –0.21 logMAR (95% confidence interval,
–0.30 to –0.12) in the IVB/IVT group. Mild anterior
chamber reaction was noted in four (13%) and five (16%)
eyes respectively in the IVB and IVB/IVT groups the day
after injection, and it resolved completely in all within 1
week with no treatment. Marked anterior chamber reac-
tion occurred in one eye in the IVB group, which resolved
with topical corticosteroid and cycloplegic drops. Two
eyes (6%) in the IVB/IVT group showed an IOP rise to 23,
22, and 28 mmHg respectively, at 6, 12, and 18 weeks.
The elevated IOP was controlled with an anti-glaucoma
drop. Progression of fibrous proliferation was noticed in
one eye (3%) of the IVB group with no sign of retinal
traction. In none of the eyes was iris neovascularization
detected. No progress in lens opacity was detected during
the follow-up period.
Discussion and Conclusion
We conducted a randomized clinical trial to evaluate
the effect of intravitreal Bevacizumab with or without
triamcinolone on refractory diabetic macular oedema.
The 24-week results of this study revealed the efficacy of
Bevacizumab alone or in combination with triamcino-
lone acetonide in reducing central macular thickness. Six
weeks after the first intravitreal injection, CMT was re-
duced significantly in both the IVB and IVB/IVT groups.
This effect was also apparent 24 weeks after initiation of
the study, which corresponded to 12 weeks after the third
intravitreal injection. Although there was no significant
difference between the IVB/IVT and IVB groups in terms
of changes in BCVA throughout the follow-up period, the
beneficial effect of the IVB/IVT group appeared earlier
compared with the IVB group. Thereafter and up to final
follow-up (week 24), both treatment groups maintained
their significant effect on visual acuity. Intravitreal beva-
cizumab has recently gained popularity for treatment of
neovascular age-related macular degeneration (AMD).
Diabetic macular oedema and neovascular AMD have
common VEGF-induced pathogenic pathways. Blood-oc-
ular barrier breakdown and hyperpermeability are pres-
ent in both of these disorders. Inhibition of VEGF by a
pan-anti-VEGF drug may explain the beneficial effect of
bevacizumab when used alone or in combination with
triamcinolone acetonide in DME. Recently, the effect of
primary intravitreal Bevacizumab on DME was evalu-
ated retrospectively in 78 eyes of 64 patients13. This
treatment resulted in stability or improvement of visual
acuity, OCT, and FA at 6 months. A second injection was
required in six eyes (20%) and a third injection was
needed in three eyes (10%). Patients included in our
study had an intractable form of DME with severe visual
disturbance and less favorable visual outcome compared
with cases of primary DME. Considering the severity of
DME and in the attempt to maximize the potential effect
of Bevacizumab, we decided to perform three consecutive
injections as a loading dose in our treatment strategy.
However, we limited intravitreal triamcinolone to a sin-
gle injection to reduce the potential side-effects of this
medication. Haritoglou et al. performed a prospective
noncomparative case series study evaluating the effect of
1.25 mg intravitreal Bevacizumab on refractory DME8.
The treatment effect was achieved with at least two
intravitreal injections of Bevacizumab in most of their
patients. The results of their study were comparable
with those of the IVB group in our clinical trial in terms
of visual improvement and CMT reduction. Therefore,
we repeated the statistical analysis excluding patients
with both eyes in the study and the same results were ob-
tained. The beneficial effect of triamcinolone acetonide
on refractory DME has already been demonstrated in
several studies3,4,13–19. We decided to add IVT to IVB in
order to possibly attain more therapeutic effect. Our
study demonstrated no additive effect by IVT in terms of
anatomical results. However there was a trend toward
earlier functional effects with combined treatment. In-
travitreal Bevacizumab alone nevertheless showed the
same therapeutic effect 12 weeks after initiation of treat-
ment. Triamcinolone induced ocular hypertension devel-
oped in two eyes (6%) in the IVB/IVT group, which was
controlled with topical medications. In a study evaluat-
ing the effect of intravitreal Bevacizumab on anterior
chamber inflammatory activity in patients with neovas-
cular AMD, none of the patients had a significant, clini-
cally detectable inflammatory response within 1 week of
injection7. In our study, however, mild anterior chamber
reaction occurred in nearly one-fifth of the eyes in the
IVB and IVB/IVT groups. It disappeared spontaneously
in all eyes within 1 week. No major injection-related com-
plication was noticed in our patients. Considering the
relatively short follow-up period, this study is not infor-
mative regarding the cataractogenic effect of triamcino-
lone. The rate of cataract progression has been reported
to be 43% in a study with multiple IVT injections and 2
years follow-up4. Snellen chart was used for measure-
ment of BCVA. However, inherent shortcomings of this
chart, such as non-geometric progression of letter size,
variable number of letters per line and lack of a stan-
dardized scaling system, should be kept in mind. In sum-
mary, three consecutive injections of intravitreal
Bevacizumab resulted in CMT reduction and visual im-
provement in eyes with refractory diabetic macular oe-
dema. These anatomic and functional effects were re-
vealed in the setting of a clinical trial, which to our
knowledge is the first study of its kind in the literature.
The anatomic effect appeared 6 weeks after the first in-
jection, and was maintained up to 12 weeks after the
third injection. Addition of triamcinolone had no signifi-
cant effect on anatomic results, but resulted in a trend
toward earlier visual improvement. Further studies with
longer follow up are needed for evaluation of anatomic
and functional results and the need for repeat intra-
vitreal injections after 24 weeks.
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KLINI^KA PRIMJENA INTRAVITREALNO BEVACIZUMABA I U KOMBINACIJI
S TRIAMCINOLONOM U DIJABETI^KOM MAKULARNOM EDEMU
S A @ E T A K
Ra|ena je klini~ka studija intravitrealne primjene preparata bevacizumaba, kao i u kombinaciji s triamcinolonom.
Rezultati su pra}eni analizom OCTa, mjere}i debljinu retine u makuli, te o{trine vida. U ovom klini~kom eksperimentu
dokazano je da je najefektivnija primjena intravitrealno bevacizumaba, te da kombinacija s triamcinolonom nema bitno
bolji efekt.
S. Synek and B. Vojnikovi}: Intravitreal Bevacizumab Treatment in Diabetic Retinopathy, Coll. Antropol. 34 (2010) Suppl. 2: 99–103
103
